<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033371</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00844</org_study_id>
    <secondary_id>NCI-2013-00844</secondary_id>
    <secondary_id>N01-CN95040</secondary_id>
    <secondary_id>CDR0000069278</secondary_id>
    <secondary_id>NCI-P02-0219</secondary_id>
    <secondary_id>ID00-109</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-00109</secondary_id>
    <secondary_id>N01-CN-95040</secondary_id>
    <secondary_id>N01CN95040</secondary_id>
    <nct_id>NCT00033371</nct_id>
  </id_info>
  <brief_title>Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis</brief_title>
  <official_title>A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well giving celecoxib with or without eflornithine
      works in preventing colorectal cancer in patients with familial adenomatous polyposis.
      Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib
      and eflornithine may keep cancer from forming in patients with familial adenomatous
      polyposis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the relative efficacy of celecoxib plus eflornithine (DFMO) versus celecoxib
      plus DFMO placebo in participants with familial adenomatous polyposis (FAP), as evidenced by
      the percent change from baseline in the number of polyps in focal area(s) of the colorectum
      in participants having 5 or more &gt;= 2mm colorectal polyps with or without duodenal polyps at
      baseline.

      II. To determine the relative tolerability and safety of celecoxib + DFMO in FAP study
      participants.

      SECONDARY OBJECTIVES:

      I. To determine the percent change in polyp size in focal area(s) of the colorectum II. To
      determine the change in global colorectal polyp burden III. To determine the percent change
      in the area of plaque-like duodenal polyps in participants presenting with duodenal disease
      at baseline.

      IV. To analyze the effects of these agents on the following panel of mucosal biomarkers:
      antigen identified by monoclonal antibody Ki-67 (Ki-67), mitotic index (number and spatial
      distribution of mitoses), phosphorylated histone H3, cyclin-dependent kinase inhibitor 1A
      (p21/WAF1/Cip1), apoptosis (Terminal deoxynucleotidyl transferase dUTP nick end labeling
      [TUNEL]), apoptotic index, BCL2-associated X protein (Bax), B-cell CLL/lymphoma 2 (Bcl-2) and
      measurement of drug effects in colonic polyp and normal tissue cyclooxygenase
      (cyclooxygenase-1 [COX-1], cyclooxygenase-2 [COX-2]) protein levels, prostaglandin E2 (PGE2),
      ornithine decarboxylase and polyamines.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive celecoxib orally (PO) twice daily (BID) and placebo PO daily.

      ARM II: Patients receive celecoxib PO BID and eflornithine PO daily.

      In both arms, treatment continues for 6 months in the absence of disease progression or
      unacceptable toxicity.

      After completion of just treatment, patients are followed up at 1-2 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment.
  </why_stopped>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>Differences between average treatment effects of two study arms tested using two-sided type I error rate of 5% in two-sample t-test. If model assumptions not met by data or transformations of data, appropriate nonparametric tests (e.g. Wilcoxon rank sums test) were used to compare treatment arms - Percent change of polyp counts from baseline to 6 months, ie [(6 months - baseline) x 100]/baseline (%). For each participant, first were matched polyps between baseline &amp; 6 months by region and landmark and summed over all matched regions on number of polyps &gt;2 mm to calculate total number of polyps &gt;2 mm at baseline &amp; 6 months, respectively. For participants refusing exit colonoscopy, 0% change entered as primary endpoint. Defined ITT All: All patients; if 6-month polyp counts missing = 0% change; ITT Measurable: All participants with baseline &amp; 6 month polyp counts; ITT Evaluable: ITT Measurable participants who also took 80% of treatment, both overall as well as during final 60 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Duodenal Polyp Burden</measure>
    <time_frame>Up to 2 months after completion of study treatment</time_frame>
    <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Polyp Size in Focal Area(s) of the Colorectum</measure>
    <time_frame>Baseline up to 2 months after completion of study treatment</time_frame>
    <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Colorectal Polyp Burden</measure>
    <time_frame>Baseline up to 2 months after completion of study treatment</time_frame>
    <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in the Area of Plaque-like Duodenal Polyps</measure>
    <time_frame>Baseline up to 2 months after completion of study treatment</time_frame>
    <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Arm I: Celecoxib and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Celecoxib and Eflornithine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Given 400 mg PO twice a day</description>
    <arm_group_label>Arm I: Celecoxib and Placebo</arm_group_label>
    <arm_group_label>Arm II: Celecoxib and Eflornithine</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>SC-58635</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO to match DFMO</description>
    <arm_group_label>Arm I: Celecoxib and Placebo</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eflornithine</intervention_name>
    <description>Given PO at 0.5 gm/m^2/day rounded down to the nearest 250 mg dose (BSA of &lt; 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of &gt; 2.6 = 1,250 mg/day).</description>
    <arm_group_label>Arm II: Celecoxib and Eflornithine</arm_group_label>
    <other_name>2-difluoromethylornithine</other_name>
    <other_name>DFMO</other_name>
    <other_name>difluromethylornithine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I: Celecoxib and Placebo</arm_group_label>
    <arm_group_label>Arm II: Celecoxib and Eflornithine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I: Celecoxib and Placebo</arm_group_label>
    <arm_group_label>Arm II: Celecoxib and Eflornithine</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  REGISTRATION INCLUSION CRITERIA:

          -  Diagnosis of FAP based on any of the following will be acceptable:

               -  &gt; 100 polyps or

               -  &gt; 10 polyps and age &lt; 40 years, or &gt; 25 polyps and age &gt; 40 years and
                  characteristic family history (autosomal dominant pattern) including:

                    -  &gt; 100 polyps in a first degree family member or

                    -  &gt; 25 polyps in two relatives in two generations, including a first degree
                       family member or

                    -  Genetic diagnosis in a relative or

               -  Genetic diagnosis by in vitro synthesized protein (IVSP) or similar assay

          -  Willingness to abstain from use of nonsteroidal anti-inflammatory drugs (NSAIDs),
             including aspirin, for the duration of the study; a cardio-protective dose of aspirin
             (&gt;= 80 mg) may be permitted but must be reviewed/approved by principal investigator
             (PI)

          -  If participant is female and of child bearing potential, she agrees to participate in
             this study by providing written informed consent, has been using adequate
             contraception (e.g. abstinence, condom, intrauterine device [IUD], birth control pill,
             diaphragm and spermicide gel combination) since her last menses and will use adequate
             contraception during the study, is not lactating, and agrees to undergo a serum
             pregnancy test at baseline, month 3 and month 6; sexually active males must agree to
             use an accepted and effective method of contraception

          -  Colon polyp status: the participant has an endoscopically assessable colonic and/or
             rectal segment

          -  Participant has no clinically significant hearing loss that is defined by the patient
             reporting that their hearing loss affects their everyday life and/or wears a hearing
             aide

          -  Participants whose air conduction pure tone audiogram reveals a deficit that differs
             from the age specific norm by less than 30 dB when averaged across two contiguous test
             frequencies in either ear are eligible, as long as no self-reported hearing deficit or
             tinnitus is present

          -  Willingness and ability to sign informed consent

          -  RANDOMIZATION INCLUSION CRITERIA:

          -  The individual has assessable colonic polyps remaining in the colon or rectum post
             baseline colonoscopy or flexible sigmoidoscopy

          -  Potential participants must have the following colonic or rectal polyp burden at the
             conclusion of the baseline endoscopy:

               -  Rectum:

                    -  Five or more polyps &gt;= 2 mm diameter

               -  Colon:

                    -  Five or more polyps &gt;= 2 mm diameter including:

                         -  Three quantifiable polyps &gt; 3 mm diameter, or two quantifiable polyps &gt;
                            5 mm diameter

                         -  In the colon, quantifiable polyps are defined as being within a
                            composite &quot;cloverleaf&quot; photograph that includes a tattoo, the appendix,
                            or the ileocecal valve

        Exclusion Criteria:

          -  REGISTRATION EXCLUSION CRITERIA:

          -  Anticipated colectomy within eight months of randomization

          -  History of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs or salicylates

          -  Chronic use of NSAIDs, including aspirin or Celebrex, at any dose during the six
             months prior to study entry will require a three-month washout period prior to
             eligibility beginning with the time of the patient's last dose; participants must
             voluntarily agree to be off all NSAIDs for three months prior to study enrollment; a
             cardio-protective dose of aspirin (&gt;= 80 mg) may be permitted but must be
             reviewed/approved by PI

          -  The use of fluconazole, lithium or chronic use of adrenocorticosteroids

          -  History in the past year of discrete gastric or duodenal ulcer of size &gt; 5 mm, except
             that those with a history of Helicobacter pylori related peptic ulcer disease will
             become eligible for study upon successfully completing antibiotic treatment of
             Helicobacter pylori

          -  History of invasive carcinoma in the past five years other than resected Duke's A/B1
             colon cancer or resected non-melanomatous skin cancer

          -  Partial or complete colectomy within 12 months prior to enrollment

          -  Inability to return for follow-up tests

          -  Significant medical or psychiatric problems, (including significant renal, hepatic or
             hematologic dysfunction) which would make the individual a poor protocol candidate

          -  Use of any investigational agent within the last 3 months, or at the discretion of the
             medical monitor

          -  History of pelvic radiation

          -  RANDOMIZATION EXCLUSION CRITERIA:

          -  Anticipated colectomy within eight months of randomization; the results of the initial
             endoscopies, including pathology reports and blood tests will be reviewed by the study
             endoscopist and surgeon prior to initiation of drug treatment to determine if the
             patient can remain on study

          -  Discrete gastric or duodenal ulcer of size &gt; 5 mm; patients with Helicobacter pylori
             related peptic ulcers of &gt; 5 mm at the time of the baseline endoscopy will become
             eligible upon endoscopically documented successful treatment of Helicobacter pylori
             and of the ulcer(s).

          -  Hemoglobin (Hgb) &lt; 10.0 gm/dl

          -  Platelet count &lt; 100,000/ml

          -  White blood cell (WBC) with differential &lt; 3,000/ml

          -  Serum glutamate pyruvate transaminase (SGPT) &gt; 1.5 x upper limit of normal, serum
             glutamic oxaloacetic transaminase (SGOT) &gt; 1.5 upper limit of normal

          -  Alkaline phosphatase &gt; 1.5 x upper limit of normal

          -  Bilirubin &gt; 2 x upper limit of normal

          -  Creatinine &gt; 1.5 x upper limit of normal

          -  Has had a positive serum pregnancy test within 14 days prior to baseline randomization

          -  Known or prior coagulopathy

          -  Elevated C-reactive protein (CRP) (&gt; 3.0 mg/L)

          -  History of cardiovascular diseases or risk factors that might include one of the
             following: myocardial infarction, angina, coronary angioplasty, congestive heart
             failure, stroke, or coronary bypass surgery

          -  Uncontrolled hypertension (&gt; 135/&gt; 85 mm Hg on three repeated measurements during the
             6 weeks prior to enrollment on the study); this pertains to subjects with known
             diagnosis of hypertension; such subjects will have been invited to participate in the
             trial following successful treatment of their known hypertension; subjects with
             diagnosis of hypertension established at study entry will be considered cases of
             potential &quot;white coat&quot; hypertension; such subjects will be otherwise evaluated for
             protocol and randomized if they agree to be monitored for blood pressure (BP); if BP
             remains persistently elevated, subjects will be allowed to remain on-study for three
             months while undergoing antihypertensive therapy and monitoring; if, at the end of 3
             months, subjects cannot demonstrate successful BP control as measured and documented
             locally, dosing will be suspended; such subjects will nevertheless be urged to
             complete 6-month off study evaluation, for intention to treat analysis

          -  Family history of premature coronary disease (i.e. onset &lt; 55 years of age)

          -  Uncontrolled diabetes; subjects with preexisting diagnosis of diabetes will be
             eligible to participate in the trial if able to document acceptable management by
             their treating physician; subjects with diagnosis of diabetes established at study
             entry will be considered cases of new onset disease; such subjects will be otherwise
             evaluated for protocol and randomized if they agree to blood sugar monitoring; if
             glucose remains persistently elevated, subjects will be allowed to remain on-study for
             three months while undergoing therapy and monitoring; of, at the end of 3 months,
             subjects cannot demonstrate successful glucose control as measured and documented
             locally, dosing will be suspended; such subjects will nevertheless be urged to
             complete 6-month off study evaluation, for intention to treat analysis

          -  Uncontrolled hypercholesteremia (low-density lipoprotein cholesterol [LDL-C] &gt; 130);
             hypercholesteremia needs to be controlled following the updated National Cholesterol
             Education Program Adult Treatment Panel III Guidelines for at least 3 months prior to
             enrollment on the study; hypercholesteremia treatment should continue during the
             entire period of Celecoxib treatment on the protocol; this pertains to subjects with
             known diagnosis of hypercholesterolemia; such subjects will have been invited to
             participate in the trial following successful treatment of their elevated cholesterol;
             subjects with diagnosis of hypercholesterolemia established at study entry will be
             considered cases of new onset disease; such subjects will be otherwise evaluated for
             protocol and randomized if they agree to cholesterol treatment and monitoring;
             subjects will be allowed to remain on-study for three months while undergoing therapy
             and monitoring; if, at the end of 3 months, subjects cannot demonstrate successful
             cholesterol control as measured and documented locally, dosing will be suspended; such
             subjects will nevertheless be urged to complete 6-month off study evaluation, for
             intention to treat analysis

          -  Metabolic syndrome diagnosis; the diagnosis of metabolic syndrome is made when three
             or more of these risk factors are present:

               -  Waist circumference: Men &gt; 102 cm (&gt; 40 in.); women &gt; 88 cm (&gt; 35 in.)

               -  Triglycerides &gt; 150 mg/dl ( &gt; 1.69 mmol/L)

               -  High-density lipoprotein cholesterol (HDL-C): Men &lt; 40 mg/dl (&lt; 1.03 mmol/L),
                  women &lt; 50 mg/dl (&lt; 1.29 mmol/L)

               -  Blood pressure &gt; 130/85 mm Hg

               -  Fasting glucose &gt; 110 mg/dl (&gt; 6.1 mmol/L)

          -  History of deep venous thrombosis, pulmonary embolism, systemic lupus erythematous,
             family history of protein S or C deficiencies, prior heparin-induced thrombocytopenia,
             Factor V Leiden deficiencies or high homocysteine levels

          -  Any indications for acetylsalicylic acid (ASA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Lynch</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>January 26, 2015</results_first_submitted>
  <results_first_submitted_qc>January 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2015</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 13, 2001 to October 21, 2008. All recruitment done in medical clinics, with the trial conducted at the University of Texas MD Anderson Cancer, the Cleveland Clinic in Cleveland and St. Mark's Hospital in Harrow, UK.</recruitment_details>
      <pre_assignment_details>Of the 205 participants with familial adenomatous polyposis (FAP) recruited, 112 were randomized. The study was closed due to slow recruitment with enrollment target almost met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I: Celecoxib and Placebo</title>
          <description>Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months (up to 200 days).</description>
        </group>
        <group group_id="P2">
          <title>Arm II: Celecoxib and Eflornithine</title>
          <description>Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose (body surface area (BSA) of &lt; 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of &gt; 2.6 = 1,250 mg/day). Treatment continues for 6 months (up to 200 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>According to the protocol, a patient needed to receive at least 80% of intended overall dose AND at least 80% dose during the final 60 days of the study to qualify as evaluable. One participant was randomized to Arm II but withdrew prior to receiving any treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I: Celecoxib and Placebo</title>
          <description>Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months (up to 200 days).</description>
        </group>
        <group group_id="B2">
          <title>Arm II: Celecoxib and Eflornithine</title>
          <description>Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose (body surface area (BSA) of &lt; 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of &gt; 2.6 = 1,250 mg/day). Treatment continues for 6 months (up to 200 days).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="18" upper_limit="63"/>
                    <measurement group_id="B2" value="38" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="B3" value="38" lower_limit="18" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Basis of FAP Diagnosis</title>
          <description>Eligible participants aged 18-65 years required to have clinical diagnosis of FAP based on personal history of one of following a)&gt;100 adenomas; b)&gt;10 adenomas before age 40 years; c)&gt;25 adenomas and, if age&gt;40 years, a characteristic family history (autosomal dominant pattern) including &gt;100 polyps in first degree family member, &gt;25 polyps in 2 relatives in two generations, genetic diagnosis in a relative, or d) genetic diagnosis by sequencing/similar assay. Participants required to have an evaluable colon and/or rectal segment, and 5 or more colorectal polyps’ ≥2mm at baseline examination.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;100 Polyps</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 Polyps and age &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;25 Polyps and age &gt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Colon versus Rectum</title>
          <description>Number of participants with intact colon (Colon); or those with rectum only (Rectum Only).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Landmark Polyps at Baseline Sceen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Baseline Screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Landmark Polyps at least 2 mm at Baseline Screen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Baseline Screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number Landmark Polyps at least 2 mm at Baseline Screen for Evaluable polyps, Evaluable Participants</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Baseline Screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaulable Participant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum</title>
        <description>Differences between average treatment effects of two study arms tested using two-sided type I error rate of 5% in two-sample t-test. If model assumptions not met by data or transformations of data, appropriate nonparametric tests (e.g. Wilcoxon rank sums test) were used to compare treatment arms - Percent change of polyp counts from baseline to 6 months, ie [(6 months - baseline) x 100]/baseline (%). For each participant, first were matched polyps between baseline &amp; 6 months by region and landmark and summed over all matched regions on number of polyps &gt;2 mm to calculate total number of polyps &gt;2 mm at baseline &amp; 6 months, respectively. For participants refusing exit colonoscopy, 0% change entered as primary endpoint. Defined ITT All: All patients; if 6-month polyp counts missing = 0% change; ITT Measurable: All participants with baseline &amp; 6 month polyp counts; ITT Evaluable: ITT Measurable participants who also took 80% of treatment, both overall as well as during final 60 days.</description>
        <time_frame>Baseline up to 6 months</time_frame>
        <population>Analysis was by intent to treat (ITT) with a total of 89 ITT participants measurable by having complete polyp information.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Celecoxib and Placebo</title>
            <description>Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months (up to 200 days).</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Celecoxib and Eflornithine</title>
            <description>Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose (body surface area (BSA) of &lt; 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of &gt; 2.6 = 1,250 mg/day). Treatment continues for 6 months (up to 200 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum</title>
          <description>Differences between average treatment effects of two study arms tested using two-sided type I error rate of 5% in two-sample t-test. If model assumptions not met by data or transformations of data, appropriate nonparametric tests (e.g. Wilcoxon rank sums test) were used to compare treatment arms - Percent change of polyp counts from baseline to 6 months, ie [(6 months - baseline) x 100]/baseline (%). For each participant, first were matched polyps between baseline &amp; 6 months by region and landmark and summed over all matched regions on number of polyps &gt;2 mm to calculate total number of polyps &gt;2 mm at baseline &amp; 6 months, respectively. For participants refusing exit colonoscopy, 0% change entered as primary endpoint. Defined ITT All: All patients; if 6-month polyp counts missing = 0% change; ITT Measurable: All participants with baseline &amp; 6 month polyp counts; ITT Evaluable: ITT Measurable participants who also took 80% of treatment, both overall as well as during final 60 days.</description>
          <population>Analysis was by intent to treat (ITT) with a total of 89 ITT participants measurable by having complete polyp information.</population>
          <units>percentage change in polyp count</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.11"/>
                    <measurement group_id="O2" value="-0.11" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT Measurable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.14"/>
                    <measurement group_id="O2" value="-0.13" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.18"/>
                    <measurement group_id="O2" value="-0.08" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Duodenal Polyp Burden</title>
        <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
        <time_frame>Up to 2 months after completion of study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Polyp Size in Focal Area(s) of the Colorectum</title>
        <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
        <time_frame>Baseline up to 2 months after completion of study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Colorectal Polyp Burden</title>
        <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
        <time_frame>Baseline up to 2 months after completion of study treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in the Area of Plaque-like Duodenal Polyps</title>
        <description>The two-sample t-test or its non-parametric analogue, the Wilcoxon rank sums test will be used.</description>
        <time_frame>Baseline up to 2 months after completion of study treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) collection was done monthly up to month 6 or early termination with all collected adverse events for randomized participants reported.</time_frame>
      <desc>Each adverse event (toxicity) reported counts once per participant. For example, if a participant had Grade 2 vomiting that increased to Grade 3 and then reduced to Grade 1 before going away, it counts as one event of Grade 3 vomiting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I: Celecoxib and Placebo</title>
          <description>Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months (up to 200 days).</description>
        </group>
        <group group_id="E2">
          <title>Arm II: Celecoxib and Eflornithine</title>
          <description>Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose (body surface area (BSA) of &lt; 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of &gt; 2.6 = 1,250 mg/day). Treatment continues for 6 months (up to 200 days).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction: Small Bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Perforation GI - Colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin Change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Low Platelet</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bloody stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hand &amp; Wrist, Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nose Bleed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rectum, Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vagina, Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia (unstable angina)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>High Frequency Hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hearing Impairment/Loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <description>Ocular/Visual</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bright lights</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Decreased vision (left eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Decreased visual acuity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Eyelid scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Near sighted</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tired eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Unequal pupils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vision-floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Watery eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Yellow discoloration (right ey</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>Burp, Distension/Bloating, Gas</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Stricture: Rectum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ulcers</sub_title>
                <description>Ileorectal Anastomosi, Rectum</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen</sub_title>
                <description>Pain</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Wrist, Arm &amp; Shoulder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <description>Flank and sides</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Breast (tenderness)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Breast bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Cardiac/Heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Ear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Groin/Loin/Thigh</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Joint/Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Oral-gums</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Rectum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Throat/Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain, Vagina (cramping)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies, seasonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Allergic reaction (food)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold Sore (mouth)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Head &amp; Nasal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Head (fungus) Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lung Infection (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Infection, Nose (yellow nasal drainage)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Infection, Right leg (spider bite)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Infection, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Infection, Ungual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Infection, Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intra-Operative Injury Extremity-Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>AST, SGOT Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Creatinine Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Elevated LDL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypercholestremia &amp; Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Muscle weakness, Extremity-lower</sub_title>
                <description>Gait and standing</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Muscle/bone soreness from fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Jaw tightness (left side)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lower jaw tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Puncture wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sutures in shoulder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive Disturbance (ADD)</sub_title>
                <description>Neurology</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mood Alteration : Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mood alteration : Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Numbness &amp; Tingling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Burning with urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Crystals in urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Irritation around genitals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <description>Pulmonary/Upper Respiratory</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nodules</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pruritis/Itching</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rash &amp; Itching</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Other skin issues</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Following reports of COX-2 inhibitor-associated cardiovascular toxicities, trial suspended from December 17, 2004 to March 18, 2005 pending reevaluation of cardiovascular risks, only two sites resumed the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Patrick Lynch, MD/Professor, Gastroenterology/Hepatology</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-794-5073</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

